SCHEMBL198609

SCHEMBL198609

N#Cc1cc(F)c(O)c(F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 2/20 0.52
ALB P02768 2/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
ESR1 P03372 2/20 0.41
ESR2 Q92731 2/20 0.41
CA12 O43570 1/20 0.40
CA2 P00918 1/20 0.40
CA3 P07451 1/20 0.40
CA6 P23280 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
PTPN11 Q06124 1/20 0.36
MMP3 P08254 1/20 0.36
TRPV4 Q9HBA0 1/20 0.36
KIF11 P52732 1/20 0.34
EGLN2 Q96KS0 3/20 0.34
CYP19A1 P11511 1/20 0.34
P4HB P07237 2/20 0.33
AR P10275 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12594013 0.84 TTR (0.48) TTRALBMEN1KMT2AESR1
SCHEMBL1312296 0.84 TTR (0.72) TTRALBMEN1KMT2AESR1
SCHEMBL3009450 0.84 TTR (0.43) TTRALBMEN1KMT2AESR1
SCHEMBL8773853 0.84 TTR (0.72) TTRALBMEN1KMT2AESR1
SCHEMBL411743 0.80 ERN1 (0.58)
SCHEMBL10493540 0.80 NFKB1 (0.45) TTRALBMEN1KMT2AAR
SCHEMBL18398312 0.80 TTR (0.44) TTRALBMEN1KMT2AESR1
SCHEMBL18002603 0.78 TTR (0.41) TTRALBMEN1KMT2AESR1
SCHEMBL7228077 0.78 MMP3 (0.57) ESR1ESR2CA12CA2CA3
SCHEMBL157603 0.78 CES2 (0.42) TTRALBMEN1KMT2ATRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773067-B2 (Trifluoromethyl)pyrimidine-2-amine compounds ELI LILLY AND COMPANY (US) 2023-10-03 US claimed
CN-122036560-A Radioactive medical isotope18F-labeled norepinephrine analogue as well as preparation method and application thereof 中国医学科学院阜外医院 2026-05-15 CN disclosed
US-12617762-B2 Carboxy derivatives with antiinflamatory properties SITRYX THERAPEUTICS LIMITED (GB) 2026-05-05 US disclosed
EP-4081511-B3 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LTD (GB) 2026-03-04 EP disclosed
WO-2025224512-A1 NOVEL COMPOUND AS 17-BETA-HYDROXYSTEROID DEHYDROGENASE 13 (HSD17B13) INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 삼진제약주식회사 2025-10-30 WO disclosed
US-20250270162-A1 KETONE INHIBITORS OF LYSINE GINGIPAIN LIGHTHOUSE PHARMACEUTICALS, INC. (US) 2025-08-28 US disclosed
US-12297322-B2 Triazine-based membranes for gas separation UT-BATTELLE, LLC (US) 2025-05-13 US disclosed
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-04-24 US disclosed
WO-2025064718-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS Interdict Bio, Inc. (US) 2025-03-27 WO disclosed
US-20250092009-A1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING CTXT PTY LTD (AU) 2025-03-20 US disclosed
EP-0734363-B1 FLUORINATION PROCESS F2 CHEMICALS LIMITED (GB) 1999-07-21 EP disclosed
US-5900502-A Fluorination process BNFL FLUOROCHEMICALS LIMITED (GB) 1999-05-04 US disclosed
US-5643929-A TREATMENT OF PICORNAVIRAL OR RHINOVIRUS AND CHEMICAL INTERMEDIATES SANOFI WINTHROP, INC. (US) 1997-07-01 US disclosed
EP-0734363-A1 FLUORINATION PROCESS BNFL FLUOROCHEMICALS LTD. (GB) 1996-10-02 EP disclosed
EP-0512352-B1 Substituted carboxylic acid derivatives HOFFMANN LA ROCHE (CH) 1996-03-27 EP disclosed
WO-1995016649-A1 FLUORINATION PROCESS BNFL FLUOROCHEMICALS LTD. (GB) 1995-06-22 WO disclosed
US-5349068-A 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents STERLING WINTHROP INC. (US) 1994-09-20 US disclosed
US-5344843-A Carnitine acryltransferase enzyme inhibitors as antiischemic agents and for cardiovascular disorders HOFFMAN-LA ROCHE INC. (US) 1994-09-06 US disclosed
EP-0512352-A2 Substituted carboxylic acid derivatives F. HOFFMANN-LA ROCHE AG (CH) 1992-11-11 EP disclosed
EP-0219143-A1 Synergistic herbicidal compositions and methods of use STAUFFER CHEMICAL COMPANY (US) 1987-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11773067-B2 (Trifluoromethyl)pyrimidine-2-amine compounds P2RX1, P2RX2, P2RY1 TTR 3174/4885ALB 3601/4885MEN1 3618/4885
US-20250129021-A1 SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS MYC, KRAS, NRAS TTR 1278/4885ALB 1014/4885MEN1 798/4885
US-20250270162-A1 KETONE INHIBITORS OF LYSINE GINGIPAIN PHYKPL, ENPEP, PREP TTR 3604/4885ALB 4774/4885MEN1 1912/4885
US-12617762-B2 Carboxy derivatives with antiinflamatory properties CCR1, CBR1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 TTR 3962/4885ALB 2545/4885MEN1 4588/4885
US-20250092009-A1 SUBSTITUTED CONDENSED THIOPHENES AS MODULATORS OF STING STING1, CGAS, IRF3 TTR 4170/4885ALB 3584/4885MEN1 1930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.